Syntheses, Structures, and Reactivity of New Pentamethylcyclopentadienyl-Rhodium(III) and -iridium(III) 4-Acyl-5-Pyrazolonate Complexes

Enantiopure Cyclometalated Rh(III) and Ir(III) Complexes Displaying Rigid Configuration at Metal Center: Design, Structures, Chiroptical Properties and Role of the Iodide Ligand

Enantiopure N-heterocyclic carbene half-sandwich metal complexes of the general formula [Cp*M(C^C:)I] (M = Rh, Ir; C^C: = NI-NHC; NI-H = Naphthalimide; NHC = N-heterocyclic carbene) are reported. The rhodium compound was obtained as a single isomer displaying six membered metallacycle and was resolved on chiral column chromatography to the corresponding enantiomers (S)-[Cp*Rh(C^C:)I] (S)-2 and (R)-[Cp*Rh(C^C:)I] (R)-2. The iridium congener, however, furnishes a pair of regioisomers, which were resolved into (S)-[Cp*Ir(C^C:)I] (S)-3 and (R)-[Cp*Ir(C^C:)I] (R)-3 and (S)-[Cp*Ir(C^C:)I] (S)-4 and (R)-[Cp*Ir(C^C:)I] (R)-4. These regioisomers differ from each other, only by the size of the metallacycle; five-membered for 3 and six-membered for 4. The molecular structures of (S)-2 and (S)-4 are reported. Moreover, the chiroptical properties of these compounds are presented and discussed. These compounds display exceptional stable configurations at the metal center in solution with enantiomerization barrier ΔG≠ up to 124 kJ/mol. This is because the nature of the naphthalimide-NHC clamp ligand and the iodide ligand contribute to their configuration’s robustness. In contrast to related complexes reported in the literature, which are often labile in solution.

Fifteen Years of Scientific Investigation into Main Groups and Transition Metal Coordination Chemistry with Allan White

The outcomes of the investigations on the structures and reactivity of a massive number of main group and transition metal complexes containing different families of ligands are reviewed. All the data result from the scientific collaboration between the research groups of Claudio Pettinari and Allan White which lasted fifteen years.

Synthesis and preliminary biological evaluation for the anticancer activity of organochalcogen (S/se) tethered chrysin-based organometallic RuII(η6-p-cymene) complexes

Organochalcogen (S/Se) functionalized chrysin derivatives were synthesized and coordinated with Ru^II(η⁶-p-cymene) to efficiently form ruthenium-based chemotherapeutic drug entities [C₃₁H₃₅O₄SRuCl]; [C₃₁H₃₅O₄SeRuCl]; [C₃₃H₃₁O₄SRuCl]; and [C₃₃H₃₁O₄SeRuCl]. The complexes were thoroughly characterized by analytical and various spectroscopic techniques which include elemental analysis, UV-vis, IR, NMR (¹H, ¹³C, and ⁷⁷Se NMR), and HR-MS. The interaction studies of these Ru(II) complexes were carried out with CT DNA/HSA by employing UV-vis, fluorescence and circular dichroic techniques in view to examine their chemotherapeutic potential. The complexes demonstrated predominant binding toward CTDNA via electrostatic interaction while, the extent of binding was quantified by calculating intrinsic binding constant (K_b) and binding constant (K) values which revealed higher binding affinity of selenium-based chrysin complexes as compared to their thio-analogs, following the order [C₃₁H₃₅O₄SeRuCl] > [C₃₃H₃₁O₄SeRuCl] > [C₃₁H₃₅O₄SRuCl] > [C₃₃H₃₁O₄SRuCl]. Moreover, interaction of these complexes with human serum albumin (HSA) was also investigated which suggested spontaneous interactions of complexes with the protein by hydrogen bonding and van der Waals forces. To visualize the preferential binding sites and affinity of complexes with DNA and HSA molecular docking studies were performed. Additionally, in vitro anticancer activity of the complexes were evaluated by SRB assay on selected cancer cell lines viz., HeLa (cervical), MIA-PA-CA-2 (pancreatic), MCF-7 (breast), Hep-G2 (Hepatoma), and SK-OV-3 (ovarian) which exhibited the superior cytotoxicity of complex [C₃₁H₃₅O₄SeRuCl] as compared to other analogs on selective cancer phenotypes. Communicated by Ramaswamy H. Sarma.

Cytotoxic Half-Sandwich Rh(III) and Ir(III) β-Diketonates

A series of half-sandwich pentamethylcyclopentadienyl rhodium(III) and iridium(III) complexes [Cp*M(DBM/HDB/AVB)Cl] and [Cp*M(DBM/HDB/AVB)(PTA)][SO₃CF₃], where Cp* = pentamethylcyclopentadienyl, the proligands DBMH = dibenzoylmethane, HDBH = o-hydroxydibenzoylmethane, AVBH = avobenzone, and PTA = 1,3,5-triaza-7-phosphaadamantane, is reported. All the complexes were characterized by IR, ¹H and ¹³C NMR spectroscopy, electrospray ionization mass spectrometry, elemental analysis, and DFT calculations. Five of the complexes have also been characterized in the solid-state by X-ray crystallography. The cytotoxicity of the complexes has been evaluated against human ovarian A2780 and A2780cisR cell lines and, with the only exception of complexes 1 and 2 that display a negligible cytotoxicity, exhibit moderate cytotoxicity toward both cancer cell lines. However, the complexes do not show cancer cell selectivity with respect to human embryonic kidney HEK293 cells.

Synthesis, Structure, and Anticancer Activity of Arene-Ruthenium(II) Complexes with Acylpyrazolones Bearing Aliphatic Groups in the Acyl Moiety

A series of neutral ruthenium(II) arene complexes [(arene)Ru(Q^R)Cl] (arene = p-cymene (cym) or hexamethylbenzene (hmb)) containing 4-acyl-5-pyrazolonate Q^R ligands with different electronic and steric substituents (R = 4-cyclohexyl, 4-stearoyl, or 4-adamantyl) and related ionic complexes [(arene)Ru(Q^R)(PTA)][PF₆] (PTA = 1,3,5-triaza-7-phosphaadamantane) were synthesized and characterized by spectroscopy (IR, UV-vis, ESI-MS, and ¹H and ¹³C NMR), elemental analysis, X-ray crystallography, and density functional theory studies. The cytotoxicity of the proligands and metal complexes was evaluated in vitro against human ovarian carcinoma cells (A2780 and A2780cisR), as well as against nontumorous human embryonic kidney (HEK293) cells. In general the cationic PTA-containing complexes are more cytotoxic than their neutral precursors with a chloride ligand in place of the PTA. Moreover, the complexes do not show cross-resistance and are essentially equally cytotoxic to both the A2780 and A2780cisR cell lines, although they only show limited selectivity toward the cancer cell lines.

Self-assembly of arene ruthenium acylpyrazolone fragments to tetranuclear metallacycles. Molecular structures and solid-state 15N CPMAS NMR correlations

Mono- and tetranuclear Ru(ii) half-sandwich complexes containing acylpyrazolone ligands. ¹³C and ¹⁵N solid state NMR spectroscopy.

Organometallic rhodium(III) and iridium(III) cyclopentadienyl complexes with curcumin and bisdemethoxycurcumin co-ligands

A series of half-sandwich cyclopentadienyl rhodium(III) and iridium(III) complexes of the type [Cp*M(curc/bdcurc)Cl] and [Cp*M(curc/bdcurc)(PTA)][SO3CF3], in which Cp* = pentamethylcyclopentadienyl, curcH = curcumin and bdcurcH = bisdemethoxycurcumin as O^O-chelating ligands, and PTA = 1,3,5-triaza-7-phosphaadamantane, is described. The X-ray crystal structures of three of the complexes, i.e. [Cp*Rh(curc)(PTA)][SO3CF3] (5), [Cp*Rh(bdcurc)(PTA)][SO3CF3] (6) and [Cp*Ir(bdcurc)(PTA)][SO3CF3] (8), confirm the expected "piano-stool" geometry. With the exception of 5, the complexes are stable under pseudo-physiological conditions and are moderately cytotoxic to human ovarian carcinoma (A2780 and A2780cisR) cells and also to non-tumorigenic human embryonic kidney (HEK293) cells, but lack the cancer cell selectivity observed for related arene ruthenium(II) complexes.

Arene-ruthenium(II) acylpyrazolonato complexes: apoptosis-promoting effects on human cancer cells

A series of ruthenium(II) arene complexes with the 4-(biphenyl-4-carbonyl)-3-methyl-1-phenyl-5-pyrazolonate ligand, and related 1,3,5-triaza-7-phosphaadamantane (PTA) derivatives, has been synthesized. The compounds have been characterized by NMR and IR spectroscopy, ESI mass spectrometry, elemental analysis, and X-ray crystallography. Antiproliferative activity in four human cancer cell lines was determined by MTT assay, yielding dose- and cancer cell line-dependent IC50 values of 9-34 μM for three hexamethylbenzene-ruthenium complexes, whereas the other metal complexes were much less active. Apoptosis was the mechanism involved in the anticancer activity of such compounds. In fact, the hexamethylbenzene-ruthenium complexes activated caspase activity, with consequent DNA fragmentation, accumulation of pro-apoptotic proteins (p27, p53, p89 PARP fragments), and the concomitant down-regulation of antiapoptotic protein Bcl-2. Biosensor-based binding studies indicated that the ancillary ligands were critical in determining the DNA binding affinities, and competition binding experiments further characterized the nature of the interaction.

A cyclometalated iridium(III) complex with enhanced phosphorescence emission in the solid state (EPESS): synthesis, characterization and its application in bioimaging

Iridium(III) complexes with intense phosphorescence in solution have been widely applied in organic light-emitting diodes, chemosensors and bioimaging. However, little attention has been paid to iridium(III) complexes showing weak phosphorescence in solution and enhanced phosphorescence emission in the solid state (EPESS). In the present study, two β-diketonate ligands with different degrees of conjugation, 1-phenyl-3-methyl-4-benzoyl-5-pyrazolone (HL1) and 1-phenyl-3-methyl-4-phenylacetyl-5-pyrazolone (HL2), have been synthesized to be used as ancillary ligands for two iridium(III) complexes, Ir(ppy)(2)(L1) and Ir(ppy)(2)(L2) (Hppy = 2-phenylpyridine). The two complexes have been characterized by single-crystal X-ray crystallography, (1)H NMR and elemental analysis. Interestingly, Ir(ppy)(2)(L1) is EPESS-active whereas Ir(ppy)(2)(L2) exhibits moderately intense emission both in solution and as a neat film, indicating that the degree of conjugation of the β-diketone ligands determines the EPESS-activity. The single-crystal X-ray analysis has indicated that there are π-π interactions between the adjacent ppy ligands in Ir(ppy)(2)(L1) but not in Ir(ppy)(2)(L2). Finally, EPESS-active Ir(ppy)(2)(L1) has been successfully embedded in polymer nanoparticles and used as a luminescent label in bioimaging.

Areneruthenium(II) 4-Acyl-5-pyrazolonate Derivatives: Coordination Chemistry, Redox Properties, and Reactivity

Areneruthenium(II) molecular complexes of the formula [Ru(arene)(Q)Cl], containing diverse 4-acyl-5-pyrazolonate ligands Q with arene = cymene or benzene, have been synthesized by the interaction of HQ and [Ru(arene)Cl(micro-Cl)]2 dimers in methanol in the presence of sodium methoxide. The dinuclear compound [{Ru(cymene)Cl}2Q4Q] (H2Q4Q = bis(4-(1-phenyl-3-methyl-5-pyrazolone)dioxohexane), existing in the RRuSRu (meso form), has been prepared similarly. [Ru(cymene)(Q)Cl] reacts with sodium azide in acetone, affording [Ru(cymene)(Q)N3] derivatives, where Cl- has been replaced by N3-. The reactivity of [Ru(cymene)(Q)Cl] has also been explored toward monodentate donor ligands L (L = triphenylphosphine, 1-methylimidazole, or 1-methyl-2-mercaptoimidazole) and exo-bidentate ditopic donor ligands L-L (L-L = 4,4'-bipyridine or bis(diphenylphosphino)propane) in the presence of silver salts AgX (X = SO3CF3 or ClO4), new ionic mononuclear complexes of the formula [Ru(cymene)(Q)L]X, and ionic dinuclear complexes of the formula [{Ru(cymene)(Q)}2L-L]X2 being obtained. The solid-state structures of a number of complexes were confirmed by X-ray crystallographic studies. Their redox properties have been investigated by cyclic voltammetry and controlled potential electrolysis, which, on the basis of their measured RuII/III reversible oxidation potentials, have allowed the ordering of the bidentate acylpyrazolonate ligands according to their electron-donor character and are indicative of a small dependence of the HOMO energy upon the change of the monodentate ligand. This is accounted for by DFT calculations, which show a relevant contribution of acylpyrazolonate ligand orbitals to the HOMOs, whereas that from the monodentate ligand is minor.